STOCK TITAN

RenovoRx, Inc. - $RNXT STOCK NEWS

Welcome to our dedicated page for RenovoRx news (Ticker: $RNXT), a resource for investors and traders seeking the latest updates and insights on RenovoRx stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect RenovoRx's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of RenovoRx's position in the market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.75%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.37%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.96%
Tags
conferences clinical trial
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
14.21%
Tags
conferences
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.06%
Tags
none
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.33%
Tags
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.63%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.33%
Tags
conferences
RenovoRx, Inc.

Nasdaq:RNXT

RNXT Rankings

RNXT Stock Data

31.13M
15.38M
11.77%
1.96%
0.1%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
SAN JOSE

About RNXT

renovorx is a medical device company headquartered in silicon valley, california. we are developing innovative solutions for targeted delivery of fluids, including diagnostic and therapeutic agents, to selected sites in the peripheral vascular system. the ability to deliver these materials at high concentration to specific vasculature, safely and without perfusion overlap to other regions, is a central paradigm of our technology. we have received fda clearance for the renovocath™ rc120 and are now introducing our innovative technology to the clinical market. renovorx is a highly motivated team with broad experience and an exciting vision for the future of targeted delivery. we are backed by a broad medical advisory board and a strong board of directors. please contact us at info@renovorx.com to learn more.